← Leaderboards
Philip D Greenberg
University Of Washington
$22,941,903
Attributed
$22,941,903
Total exposure
21
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,811,552 · 22
By mechanism
P01$11,754,456 · 8
R01$5,763,684 · 1
R37$3,500,639 · 1
U01$2,553,549 · 1
P51$806,550 · 6
P30$700,853 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Pamela J Fink$12,911,564
- Paul L Bollyky$18,103,558
- Joan M Goverman$14,685,279
- Lisa M Frenkel$29,105,317
- Romel D Mackelprang$4,761,625
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyMalignant NeoplasmsTumorSuccessTumor AntigensT-LymphocyteAntigensInsightClinical TrialsImmuneT Cell TherapyClinical ResearchCd8b1 GeneReagentTumor MicroenvironmentResponseImmune SystemImmune ResponseMediatingTranslatingAffinityCellsDesignAvidity
Grant awards (72)
Project 2: Treating metastatic lung cancer by targeting mutated KRAS with engineered T cells$308,964
P50 · FY2025 · CA · contact PI
Project 1: Transgenic TCR-mediated tumor therapy$579,552
P01 · FY2023 · CA · contact PI
Project 1: Transgenic TCR-mediated tumor therapy$899,284
P01 · FY2022 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$823,013
P01 · FY2022 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$904,588
P01 · FY2021 · CA · contact PI
Project 1: Transgenic TCR-mediated tumor therapy$682,429
P01 · FY2021 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$327,515
P01 · FY2021 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$907,233
P01 · FY2020 · CA · contact PI
Project 1: Transgenic TCR-mediated tumor therapy$669,971
P01 · FY2020 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$815,880
P01 · FY2019 · CA · contact PI
Project 1: Transgenic TCR-mediated tumor therapy$496,050
P01 · FY2019 · CA · contact PI
Research Program: Immunology and Vaccine Development$87,210
P30 · FY2019 · CA · contact PI
Research Program: Immunology and Vaccine Development$9,134
P30 · FY2019 · CA · contact PI
Research Program: Immunology and Vaccine Development$7,406
P30 · FY2019 · CA · contact PI
Research Program: Immunology and Vaccine Development$3,702
P30 · FY2019 · CA · contact PI
Research Program: Immunology and Vaccine Development$2,890
P30 · FY2019 · CA · contact PI
Specific Adoptive Immunotherapy of AML with Engineered CD8+ T Cells$838,209
P01 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$87,209
P30 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$9,134
P30 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$8,333
P30 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$7,406
P30 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$2,890
P30 · FY2018 · CA · contact PI
Research Program: Immunology and Vaccine Development$1,234
P30 · FY2018 · CA · contact PI
Mechanisms of Murine Turmor Eradication by Immunotherapy$574,748
R01 · FY2017 · CA · contact PI
Research Program: Immunology and Vaccine Development$119,013
P30 · FY2017 · CA · contact PI
Mechanisms of Murine Turmor Eradication by Immunotherapy$576,505
R01 · FY2016 · CA · contact PI
Research Program: Immunology and Vaccine Development$87,231
P30 · FY2016 · CA · contact PI
Mechanisms of Murine Turmor Eradication by Immunotherapy$536,912
R01 · FY2015 · CA · contact PI
Research Program: Immunology and Vaccine Development$89,613
P30 · FY2015 · CA · contact PI
Mechanisms of Murine Turmor Eradication by Immunotherapy$521,765
R01 · FY2014 · CA · contact PI
Chromatin states encoding fate commitment and plasticity of tolerant CD8 T cells$231,750
R21 · FY2014 · AI · contact PI
Mechanisms of Murine Turmor Eradication by Immunotherapy$552,495
R01 · FY2013 · CA · contact PI
Chromatin states encoding fate commitment and plasticity of tolerant CD8 T cells$181,538
R21 · FY2013 · AI · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$533,495
R01 · FY2011 · CA · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$552,612
R01 · FY2010 · CA · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$544,421
R01 · FY2009 · CA · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$310,881
R01 · FY2009 · CA · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$531,207
R01 · FY2008 · CA · contact PI
Mechanisms of Murine Tumor Eradication by Immunotherapy$528,643
R01 · FY2007 · CA · contact PI
Biologic Activity of Transferred HIV-specific CD8 Clones$214,748
U01 · FY2007 · AI · contact PI
SAFETY AND ANTIVIRAL EFFICACY OF IMMUNOTHERAPY WITH AUTOLOGOUS CD8+ HIV-SPECIFIC$9,569
M01 · FY2007 · RR · contact PI
Biologic Activity of Transferred HIV-specific CD8 Clones$591,387
U01 · FY2006 · AI · contact PI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$567,199
R37 · FY2006 · CA · contact PI
ADOPTIVE TRANSFER OF SHIV-SPECIFIC CD8+ T CELLS$228,467
P51 · FY2006 · RR · contact PI
Biologic Activity of Transferred HIV-specific CD8 Clones$591,671
U01 · FY2005 · AI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$566,963
R37 · FY2005 · CA
ADOPTIVE TRANSFER OF AUTOLOGOUS SHIV-SPECIFIC CD+-T CELLS$175,831
P51 · FY2005 · RR
Biologic Activity of Transferred HIV-specific CD8 Clones$577,151
U01 · FY2004 · AI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$553,481
R37 · FY2004 · CA
ADOPTIVE TRANSFER OF AUTOLOGOUS SHIV-SPECIFIC CD+-T CELLS$134,416
P51 · FY2004 · RR
Biologic Activity of Transferred HIV-specific CD8 Clones$578,592
U01 · FY2003 · AI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$473,539
R37 · FY2003 · CA
ENHANCEMENT OF IMMUNE RESPONSIVENESS TO VACC. BY TREATMENT WITH ANTI-CTLA-4$67,715
P51 · FY2003 · RR
ADOPTIVE TRANSFER OF AUTOLOGOUS SHIV-SPECIFIC CD*+-T CELLS$67,715
P51 · FY2003 · RR
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$459,747
R37 · FY2002 · CA
SPECIFIC ADOPTIVE IMMUNOTHERAPY OF MALIGNANT DISEASES$0
P01 · FY2002 · CA
CORE--MOLECULAR IMMUNOLOGY$0
P30 · FY2002 · AI
CELLULAR IMMUNE RESPONSES TO SUBUNIT IMMUNODEFICIENCY VIRUS VACCINES$0
P01 · FY2002 · AI
THERAPY OF HIV WITH GENETICALLY MODIFIED T CELL CLONES$1,454,188
P01 · FY2001 · AI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$446,356
R37 · FY2001 · CA
ADOPTIVE TRANSFER OF SIV SPECIFIC CD8+ T CELL CLONES IN MACAQUES$0
P51 · FY2001 · RR
CORE--MOLECULAR IMMUNOLOGY$0
P30 · FY2001 · AI
SPECIFIC ADOPTIVE IMMUNOTHERAPY OF VIRAL DISEASES$0
P01 · FY2001 · CA
TRANSFER OF HIV-SPECIFIC CD4+ T CELL CLONES WITH GENES INHIBITING HIV$0
P01 · FY2001 · AI
CELLULAR IMMUNE RESPONSES TO SUBUNIT IMMUNODEFICIENCY VIRUS VACCINES$0
P01 · FY2001 · AI
THERAPY OF HIV WITH GENETICALLY MODIFIED T CELL CLONES$1,415,461
P01 · FY2000 · AI
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY$433,354
R37 · FY2000 · CA
SPECIFIC ADOPTIVE IMMUNOTHERAPY OF VIRAL DISEASES$346,443
P01 · FY2000 · CA
CELLULAR IMMUNE RESPONSES TO SUBUNIT IMMUNODEFICIENCY VIRUS VACCINES$343,350
P01 · FY2000 · AI
TRANSFER OF HIV-SPECIFIC CD4+ T CELL CLONES WITH GENES INHIBITING HIV$251,290
P01 · FY2000 · AI
CORE--MOLECULAR IMMUNOLOGY$178,448
P30 · FY2000 · AI
ADOPTIVE TRANSFER OF SIV SPECIFIC CD8+ T CELL CLONES IN MACAQUES$132,406
P51 · FY2000 · RR